Short answer
LifeStance Health Group, Inc. (LFST) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $456M (up 25.3% year over year) with net income of $22M.
Q3 2026 key financials · XBRL
- Revenue
- $456M
- +25.3% YoY · +4.7% QoQ
- Net income
- $22M
- +1978.5% YoY · −5.2% QoQ
- Operating margin
- 7.3%
Source: XBRL data from the LifeStance Health Group, Inc. (LFST) Q3 2026 10-Q on SEC EDGAR. USD.
LifeStance Health Group, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $455.9M, up 25% YoY from $363.8M, driven by 17% higher visits and modest payor rate increases
- Operating margin 7.3% vs 2.0% YoY, with income from operations $33.1M vs $7.4M
- Center Margin $161.4M vs $116.6M, up 38%; Adjusted EBITDA $68.4M vs $40.2M
- Nine-month operating cash flow $170.0M vs $88.6M; share repurchases $24.8M during the quarter
- Outlook: revenue growth from clinician recruiting, acquisitions, new centers and virtual sessions; near-term center and G&A investment headwinds
Risk Factors
- Ownership concentration: TPG and Summit collectively own approximately 25.3%, limiting stockholder influence over control transactions
- Governance transition: Loss of Nasdaq controlled-company status triggered phased independent committee requirements over one year
- Compliance exposure: Governance exemptions remain available during the transition, reducing stockholder protections
- Conflict risk: Principal Stockholders may invest in competitors or pursue acquisitions unavailable to LifeStance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LifeStance Health Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.